Coree Italy’s commitment to the study of new natural enhancers of mucosal vaccinations
CoreeGroup chooses Italy to study a probiotic that enhances the immune response
The new preparation will be studied, in particular, to be combined as a “booster” to mucosal vaccination, a form of vaccine administration such as that using nasal sprays or oral drops that offers many advantages: lower costs, greater accessibility to vaccination, needleless administration and greater capacity for mass vaccinations in emergency situations, such as during pandemics.
The pharmaceutical company Coree Italy has applied for a patent for a preparation based on a proprietary probiotic strain
A new European patent application has been filed by Coree Italia for a new probiotic strain capable of enhancing the immune response.
Coree has always dedicated much effort to collaborating with leading Italian research institutes, in order to ensure the best quality of its innovation portfolio.
The completion of the preclinical phase will be carried out with the consultancy of “Istituto Mario Negri” of Milan, which will also be involved in the possible clinical development.
The safety of the preparation has been carefully evaluated on the basis of the genotypic and phenotypic characteristics of the original strain and the specific method of preparation to obtain the immuno-adjuvant.
The new preparation will be studied, in particular, to be combined as a “booster” to mucosal vaccination, a form of vaccine administration such as that using nasal sprays or oral drops that offers many advantages: lower costs, greater accessibility to vaccination, needle-free administration and greater capacity for mass vaccinations in emergency situations, such as during pandemics.
“To get the best response with this type of vaccine – says Dr. Chongyoon Lim President of CoreeGroup – a viable strategy is to enhance the necessary stimulation of the immune system, associating the mucosal vaccine with an adjuvant substance. Currently, there are many adjuvants of very different nature being developed, but only a few have sufficient potency and most of them are abandoned in the course of clinical development due to side effects and doubts about their safety.”
In this area, natural solutions, such as those offered by beneficial bacteria through their cells and their metabolic properties, are worth exploring even if the road to market requires intensive research, time and huge investments.
“For this reason, it is highly desirable to have new powerful but also safe adjuvants, to compare with those available. The probiotic object of the study will be investigated for its contribution to making mucosal vaccination safer and more effective” concludes Lim.
Coree S.r.l., founded by Dr. Chongyoon LIM, the President of the Korean pharmaceutical company Hanmi Pharmaceutical, has been working since 2017 on R&D projects including “Mother, Child and Beyond” in collaboration with Italian institutions such as the Agostino Gemelli hospital, the Catholic University, the Cà Granda pediatric hospital in Milan and the center for research on the microbiome AAT S.r.l. The Ofmom SynterAct® probiotic line, with the exclusive patent-pending blend, is one of the results of this R&D effort.
